GLP Toxicology CROs for Cynomolgus monkey Studies

4 contract research organizations in our directory list both GLP Toxicology and Cynomolgus monkey among their capabilities, across 4 countries. 4 report GLP capability and 1 reports AAALAC accreditation. Confirm species-specific experience with each lab when you get in touch.

4 CROs 4 GLP 1 AAALAC 4 countries

GLP Toxicology CROs for Cynomolgus monkey Studies

Showing 4 CROs. Order rotates daily so no lab is permanently listed first.

Shin Nippon Biomedical Laboratories (SNBL)

JP GLP

Long-established Japanese CRO with large GLP nonclinical safety facilities and deep nonhuman primate experience, supporting toxicology, safety pharmacology and pharmacokinetics.

GLP Toxicology Pharmacokinetics Repeat-Dose Toxicity Reproductive Toxicity Safety Pharmacology Cynomolgus monkey Dog Non-human Primate Rat

Alpha Genesis

US GLP AAALAC

Vertically integrated nonhuman primate CRO in South Carolina combining on-site breeding with discovery pharmacology, GLP toxicology, vaccine and gene therapy studies.

GLP Toxicology Gene Therapy Studies In Vivo Efficacy Pharmacokinetics Vaccine Development Cynomolgus monkey Mouse Non-human Primate Rat

JOINN Laboratories

CN GLP

Large China-based nonclinical CRO offering GLP safety assessment, pharmacology, pharmacokinetics and bioanalysis, with operations in China and the United States.

GLP Toxicology Bioanalysis In Vivo Efficacy Pharmacokinetics Repeat-Dose Toxicity Cynomolgus monkey Dog Non-human Primate Rat

K-Prime Research (BTT Group)

KR GLP

Korean nonhuman primate CRO in the Biotoxtech group with GLP repeat-dose toxicity and cardiovascular safety pharmacology in NHPs, plus NHP inhalation studies.

GLP Toxicology Cardiovascular Safety Inhalation Toxicity Repeat-Dose Toxicity Safety Pharmacology Cynomolgus monkey Non-human Primate

Questions to ask when choosing a GLP Toxicology in Cynomolgus monkey CRO

  • When was your most recent FDA or OECD GLP inspection, and were there findings?
  • Which species and routes do you routinely run under GLP?
  • Who will be the study director, and how many concurrent studies do they carry?